Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients with Relapsing Multiple Sclerosis By admin / 02/24/2022
Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
Long-term Follow-up Results From the Phase 2 Multicenter Study of Ublituximab(UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients With Relapsing Multiple Sclerosis (RMS) By admin / 02/27/2020
Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis (RMS) By admin / 02/28/2019
6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis By admin / 02/01/2018
